Current partner codePEPTIDESDE
PeptideStat
Menu

Vendors

Compare pricesVendor directoryVendor reviewsDiscount codesLab tests & COAs

Research

ResearchDatabaseClinical trials

Tools

All calculatorsReconstitutionAccumulationUnit converterPeptide chemistry
ApprovedWeight lossSubcutaneousEvidence 5/5

Tirzepatide

Also known as: LY3298176, Mounjaro, Zepbound

Activates GLP-1 and GIP receptors to improve glycemic control and reduce appetite + body weight.

Read full research guideView clinical trialsBuy / compare source

This page is a structured profile. Narrative evidence, dosing context and FAQs live on the research guide — not duplicated here as a second full article.

Illustrative subcutaneous database profile for Tirzepatide
Illustrative profileSubcutaneous
Database profileApproved
TirzepatideWeight loss
Drug class
Dual agonist (GLP-1 / GIP)
Primary targets
GLP-1R, GIPR
Dose reference
2.5–15 mg once weekly
Half-life
~5 days
Developer / origin
Eli Lilly
Reference year
2022
Evidence score
5/5 - Approved with large human trials

Approved uses

  • Type 2 diabetes
  • Chronic weight management
Evidence 5/5

Approved with large human trials

Tirzepatide has large randomized obesity and diabetes trials plus FDA-regulated labeling for approved indications.

Approved medication with substantial human clinical evidence.

Evidence basis

  • Large human RCTs
  • FDA-regulated labeling
  • Approved for type 2 diabetes and chronic weight management

How to read this entry

Dose references and half-life values are pulled from trial protocols, labels, reviews, or published summaries where available. They are context for research and comparison, not a personal dosing recommendation.

Status matters: approved drugs have regulated indications; investigational compounds are still being studied; research-only peptides do not have established human dosing, safety, or efficacy for consumer use.

Tirzepatide guides

Read the matching guide or adjacent research pages for more context.

Is Mounjaro a GLP-1? Yes — and Also Something More (Tirzepatide Explained)Mounjaro is a GLP-1 receptor agonist, but it's also a GIP agonist — a dual-action drug that outperforms single-receptor GLP-1s on weight loss. What that second target means in practice.CagriSema: Cagrilintide + Semaglutide Trial Results, Status and LimitsCagriSema is Novo Nordisk’s investigational amylin + GLP-1 combination. Trial averages look strong, but it is not approved and is not a DIY stack of research vials.Peptides for Weight Loss: GLP-1s, Tirzepatide, Retatrutide and What WorksA broad guide to weight-loss peptides, from approved GLP-1 and dual-incretin medicines to investigational retatrutide, cagrilintide and other research compounds.What Is GLP-1? The Hormone, the Drugs, and Why They WorkGLP-1 is a gut hormone released after eating. Agonist drugs amplify that effect — slowing digestion, blunting appetite and steadying blood sugar.

Tirzepatide calculator shortcuts

Open peptide calculators with editable Tirzepatide example values already filled in.

Tirzepatide reconstitution calculatorPrefills a 10 mg vial, 2 mL BAC water and editable dose fields.Open prefilled toolTirzepatide accumulation calculatorPrefills 120 hour half-life and 168 hour interval examples.Open prefilled toolTirzepatide unit converterPrefills 2.5 mg with a 10 mg vial example.Open prefilled tool

Peptide calculators

Use calculators for concentration, unit conversion and repeated-dose accumulation math.

Peptide reconstitution calculatorCalculate concentration, draw volume and syringe units from vial strength and BAC water.Open toolPeptide accumulation calculatorModel repeated dosing schedules with half-life, interval, peak and trough estimates.Open toolPeptide unit converterConvert mg, mcg, optional IU and syringe units from one reconstituted vial setup.Open toolPeptide chemistry calculatorAnalyze sequence length, molecular weight, composition, charge, hydropathy and notation.Open tool

Compare with related peptides

Stay inside the same research category and compare mechanism, status and evidence quality.

Retatrutide

LY3437943

4/5
Weight lossInvestigational

Activates GLP-1, GIP and glucagon receptors simultaneously to suppress appetite and raise energy expenditure.

DetailsGuide

Semaglutide

Ozempic, Wegovy, Rybelsus

5/5
Weight lossApproved

Mimics the incretin GLP-1, slowing gastric emptying and reducing appetite while improving insulin secretion.

DetailsGuide

Liraglutide

Victoza, Saxenda

5/5
Weight lossApproved

Daily GLP-1 analog. Reduces appetite and improves glycemic control via the same incretin pathway as semaglutide.

DetailsGuide
4/5
Weight lossInvestigational

Long-acting amylin analog that slows gastric emptying and reinforces satiety; studied in combination with semaglutide (CagriSema).

Details

Category hub

Open the category page for the full comparison table and FAQ.

Weight Loss Peptides

Compare weight loss peptides including GLP-1, GIP, amylin and triple-agonist compounds by approval status, mechanism, half-life and evidence score.

Read this first

PeptideStat is educational, not medical advice. Many compounds we cover are investigational or research-only and are not approved for human use. Partner links may earn us a commission without changing your price or our editorial conclusions.

Full disclosure →